<DOC>
	<DOCNO>NCT03031691</DOCNO>
	<brief_summary>A Phase 1b Dose Escalation Study Safety Pharmacodynamics Brontictuzumab Combination Chemotherapy Subjects Previously Treated Metastatic Colorectal Cancer .</brief_summary>
	<brief_title>A Study Brontictuzumab With Chemotherapy Subjects With Previously Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This phase 1b dose escalation study safety pharmacodynamics brontictuzumab combination chemotherapy subject previously treat metastatic colorectal cancer . This study consist screen period , treatment period post-treatment follow period patient follow survival 24 month . Patients enrol two stage : dose-escalation stage expansion phase . Approximately 34 patient enrol study approximately 5 study center United States .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Histologically confirm metastatic colorectal cancer ( mCRC ) previously treat fluoropyrimidine , oxaliplatin irinotecanbased chemotherapy , antiVEGF biological therapy , KRAS wildtype , antiEGFR therapy ECOG performance status 0 1 Prior treatment gamma secretase inhibitor Notch 1 inhibitor Subjects know active HIV infection . Subjects HIV stable antiretroviral regimen evidence immune deficiency ( normal CD4 count ) , undetectable viral load , HIVrelated infection eligible Subjects uncontrolled diarrhea &lt; 30 day prior first administration study drug Subjects history current clinically significant gastrointestinal disease include , limited : Inflammatory bowel disease ( include ulcerative colitis Crohn 's disease ) Active peptic ulcer disease Known intraluminal metastatic lesion ( ) risk bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>